Fig. 25

a Schematic of the formation of the CuAl-LDH and GSH-induced enhancement of catalysis in cancer cells. b Pharmacokinetic curve of nanosheets, showing the concentration of the nanozyme in the blood plasma as a function of time. The blood circulation halftime of the nanosheets was approximately 7.23 ± 0.24 h. c Biodistribution of CuAl-LDH, showing its high concentrations in tumors, lungs, liver, and kidneys. d Tumor volume in 4T1 tumor-bearing mice (control groups) and activation group treated with the resveratrol precursors and nanozyme. e H&E staining showing the difference in tissue morphology in the control and treatment group and indicating substantially less tissue damage in the nanozyme activation group than in the controls. Reprinted from Ref. [201] with permission from Elsevier Inc. Copyright 2022